{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:25:39Z","timestamp":1793219139030,"version":"4.5.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Non-infectious inflammatory ocular diseases pose significant challenges in diagnosis and management, often requiring systemic immunosuppressive therapy. Since Janus kinase (JAK) inhibitors may represent a novel therapeutic option for these disorders, the present study aimed to expand current knowledge about their efficacy and safety in patients with these conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective cohort study included 12 adult patients from the international AutoInflammatory Disease Alliance (AIDA) Network registries dedicated to non-infectious ocular inflammatory conditions. We assessed ocular flares, visual acuity, disease course, and complications before and after initiating JAK inhibitor therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ocular inflammation was related to a systemic disease in 8 (66.7%) patients as follows: spondyloarthritis (\n                      <jats:italic>n<\/jats:italic>\n                      = 3), peripheral psoriatic arthritis (\n                      <jats:italic>n<\/jats:italic>\n                      = 1), rheumatoid arthritis (\n                      <jats:italic>n<\/jats:italic>\n                      = 1), antinuclear antibodies (ANA) positive juvenile idiopathic arthritis (\n                      <jats:italic>n<\/jats:italic>\n                      = 1), Beh\u00e7et\u2019s syndrome (\n                      <jats:italic>n<\/jats:italic>\n                      = 1), Vogt-Koyanagi-Harada syndrome (\n                      <jats:italic>n<\/jats:italic>\n                      = 1). In total, 4 patients received baricitinib, 1 patient received tofacitinib, and 7 patients underwent upadacitinib treatment. The overall average duration of JAK inhibitors treatment was 8.6 \u00b1 5.5 months (ranging from 3 to 20 months). At the last assessment, ocular disease control was complete in 12\/12 patients. One patient discontinued baricitinib due to poor compliance after a 12-month relapse-free period. The incidence of ocular flares was 125 episodes\/1.000 person-months prior to the initiation of JAK inhibitors and 28.6 episodes\/1.000 person-months thereafter. The incidence rate ratio for experiencing a relapse before starting a JAK inhibitor compared to the following period was 4.37 (95% CI 1.3\u201314.7,\n                      <jats:italic>p<\/jats:italic>\n                      -value: 0.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>JAK inhibitors demonstrate efficacy and safety in controlling ocular inflammatory relapses, confirming that they represent a valuable treatment option for patients with non-infectious inflammatory ocular diseases resistant to conventional treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2024.1439338","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T01:02:36Z","timestamp":1724374956000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries"],"prefix":"10.3389","volume":"11","author":[{"given":"Antonio","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Palacios-Olid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Caggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaafar","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Hern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pelegr\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Mej\u00eda-Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zarate-Pinz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gentileschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Fonollosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Gaggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana Hussein","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Balistreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Narv\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"de-la-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8518-3","article-title":"Ocular involvement in systemic autoimmune diseases.","volume":"49","author":"Generali","year":"2015","journal-title":"Clin Rev Allergy Immunol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(04)17554-5","article-title":"The eye in systemic inflammatory diseases.","volume":"364","author":"McCluskey","year":"2004","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2324400","article-title":"Role of Janus kinase (JAK) Inhibitor in autoimmune ocular inflammation: A systematic review.","volume":"2021","author":"Wen","year":"2021","journal-title":"J Immunol Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2019.06.007","article-title":"Adalimumab in Juvenile Idiopathic arthritis-associated uveitis: 5-year follow-up of the bristol participants of the SYCAMORE trial.","volume":"207","author":"Horton","year":"2019","journal-title":"Am J Ophthalmol."},{"key":"B5","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: Results of a phase I\/II dose-ranging, randomized, clinical trial.","volume":"121","author":"Suhler","year":"2014","journal-title":"Ophthalmology."},{"key":"B6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/jcpt.12821","article-title":"Tocilizumab for refractory uveitis associated with juvenile idiopathic arthritis: A report of two cases.","volume":"44","author":"Dipasquale","year":"2019","journal-title":"J Clin Pharm Ther."},{"key":"B7","article-title":"Cytokines in immune-mediated \u201cNon-infectious\u201d Uveitis.","author":"Kalogeropoulos","year":"2023","journal-title":"Klin Monbl Augenheilkd."},{"key":"B8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40123-022-00459-1","article-title":"Autoinflammatory diseases alliance (AIDA) network. Development and implementation of the aida international registry for patients with non-infectious uveitis.","volume":"11","author":"Della Casa","year":"2022","journal-title":"Ophthalmol Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s40123-022-00466-2","article-title":"Development and implementation of the AIDA international registry for patients with non-infectious scleritis.","volume":"11","author":"Della Casa","year":"2022","journal-title":"Ophthalmol Ther."},{"key":"B10","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s11739-022-03038-1","article-title":"Autoinflammatory diseases alliance (AIDA) Network. Development and implementation of the AIDA international registry for patients with Beh\u00e7et\u2019s disease.","volume":"17","author":"Vitale","year":"2022","journal-title":"Intern Emerg Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop.","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol."},{"key":"B12","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ophtha.2010.08.027","article-title":"A standardized grading system for scleritis.","volume":"118","author":"Sen","year":"2011","journal-title":"Ophthalmology."},{"key":"B13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/1744666X.2020.1798230","article-title":"The current status of biological treatment for uveitis.","volume":"16","author":"Gaggiano","year":"2020","journal-title":"Expert Rev Clin Immunol."},{"key":"B14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/1744666X.2023.2207823","article-title":"Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis.","volume":"19","author":"Maccora","year":"2023","journal-title":"Expert Rev Clin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2024.2323671","article-title":"Tofacitinib for refractory uveitis and scleritis in children: A case series.","volume":"5","author":"Dutta Majumder","year":"2024","journal-title":"Ocul Immunol Inflamm."},{"key":"B16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","article-title":"JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.","volume":"39","author":"Miserocchi","year":"2020","journal-title":"Clin Rheumatol."},{"key":"B17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis.","volume":"13","author":"Paley","year":"2018","journal-title":"Am J Ophthalmol Case Rep."},{"key":"B18","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4103\/ijo.IJO_998_20","article-title":"Tofacitinib in Vogt-Koyanagi-Harada disease.","volume":"68","author":"Dutta Majumder","year":"2020","journal-title":"Indian J Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/403452","article-title":"Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis.","volume":"2014","author":"Meadow","year":"2014","journal-title":"Case Rep Rheumatol."}],"updated-by":[{"DOI":"10.3389\/fmed.2024.1489092","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000}}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1439338\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T06:44:19Z","timestamp":1726209859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1439338\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":19,"alternative-id":["10.3389\/fmed.2024.1439338"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1439338","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"article-number":"1439338"}}